Inventor · disambiguated record
Jörg Kaufmann
Also filed as: KAUFMANN JOERG · KAUFMANN JOERG HEINRICH · KAUFMANN JORG · KAUFMANN JÖRG
36 granted patents·13 pending applications·849 citations·filing 1998–2024
98Inventor score
Files withSILENCE THERAPEUTICS GMBH19SILENCE THERAPEUTICS AG6SILENCE THERAPEUTICS AG AG5FEINSTEIN ELENA3KEIL OLIVER2
Top patents by PatentIndex Score
49 records- 0198US9695423B2Interfering RNA moleculesSILENCE THERAPEUTICS GMBH·Filed 2015·Granted Jul 4, 2017·46 cites·25 claims
- 0298US9222092B2Interfering RNA moleculesSILENCE THERAPEUTICS AG AG·Filed 2014·Granted Dec 29, 2015·76 cites·10 claims
- 0398US7741299B2Therapeutic uses of inhibitors of RTP801QUARK PHARMACEUTICALS INC·Filed 2005·Granted Jun 22, 2010·107 cites·12 claims
- 0498US7452987B2Interfering RNA moleculesSILENCE THERAPEUTICS AG AG·Filed 2003·Granted Nov 18, 2008·183 cites·7 claims
- 0597US8933215B2Interfering RNA moleculesSILENCE THERAPEUTICS AG AG·Filed 2012·Granted Jan 13, 2015·43 cites·19 claims
- 0697US7893245B2Interfering RNA moleculesSILENCE THERAPEUTICS AG AG·Filed 2008·Granted Feb 22, 2011·80 cites·11 claims
- 0795US9790505B2Interfering RNA moleculesSILENCE THERAPEUTICS GMBH·Filed 2017·Granted Oct 17, 2017·10 cites·23 claims
- 0895US8324370B2Interfering RNA moleculesGIESE KLAUS·Filed 2011·Granted Dec 4, 2012·46 cites·23 claims
- 0993US8017804B2Lipids, lipid complexes and use thereofSILENCE THERAPEUTICS AG·Filed 2005·Granted Sep 13, 2011·27 cites·7 claims
- 1092US9790501B2Interfering RNA moleculesSILENCE THERAPEUTICS GMBH·Filed 2017·Granted Oct 17, 2017·6 cites·30 claims
- 1192US9758784B1Interfering RNA moleculesSILENCE THERAPEUTICS GMBH·Filed 2017·Granted Sep 12, 2017·6 cites·24 claims
- 1292US7713943B2Further use of protein kinase N betaSILENCE THERAPEUTICS AG AG·Filed 2003·Granted May 11, 2010·44 cites·32 claims
- 1391US9783802B2Interfering RNA moleculesSILENCE THERAPEUTICS GMBH·Filed 2017·Granted Oct 10, 2017·5 cites·28 claims
- 1490US8357722B2Lipids, lipid complexes and use thereofSilence Therpeutics AG·Filed 2011·Granted Jan 22, 2013·8 cites·17 claims
- 1589US6248597B1Microparticle enhanced light scattering agglutination assayROCHE DIAGNOSTICS CORP·Filed 1998·Granted Jun 19, 2001·111 cites·19 claims
- 1688US9486538B2Lipids, lipid complexes and use thereofSILENCE THERAPEUTICS GMBH·Filed 2015·Granted Nov 8, 2016·3 cites·14 claims
- 1787US8309532B2Therapeutic uses of inhibitors of RTP801FEINSTEIN ELENA·Filed 2010·Granted Nov 13, 2012·7 cites·9 claims
- 1886US10329568B2Interfering RNA moleculesSILENCE THERAPEUTICS GMBH·Filed 2018·Granted Jun 25, 2019·2 cites·24 claims
- 1986US10323246B2Interfering RNA moleculesSILENCE THERAPEUTICS GMBH·Filed 2017·Granted Jun 18, 2019·2 cites·30 claims
- 2086US10266829B2Interfering RNA moleculesSILENCE THERAPEUTICS GMBH·Filed 2018·Granted Apr 23, 2019·2 cites·23 claims
- 2183US8735453B2Lipids, lipid complexes and use thereofSILENCE THERAPEUTICS AG·Filed 2013·Granted May 27, 2014·2 cites·13 claims
- 2281US8852472B2Coated lipid complexes and their useKEIL OLIVER·Filed 2005·Granted Oct 7, 2014·9 cites·48 claims
- 2380US9125820B2Lipids, lipid complexes and use thereofSILENCE THERAPEUTICS AG·Filed 2014·Granted Sep 8, 2015·1 cites·6 claims
- 2478US10774332B2Interfering RNA moleculesSILENCE THERAPEUTICS GMBH·Filed 2019·Granted Sep 15, 2020·0 cites·24 claims
- 2577US11578328B2Interfering RNA moleculesSILENCE THERAPEUTICS GMBH·Filed 2020·Granted Feb 14, 2023·0 cites·13 claims
- 2676US8168607B2Methods of treating eye diseases in diabetic patientsFEINSTEIN ELENA·Filed 2010·Granted May 1, 2012·2 cites·10 claims
- 2775US6828158B2Microparticle enhanced light scattering agglutination assayROCHE DIAGNOSTICS CORP·Filed 2001·Granted Dec 7, 2004·13 cites·10 claims
- 2873US8642571B2Therapeutic uses of inhibitors of RTP801FEINSTEIN ELENA·Filed 2012·Granted Feb 4, 2014·1 cites·19 claims
- 2973US8232256B2Means for inhibiting the expression of protein kinase 3KAUFMANN JORG·Filed 2007·Granted Jul 31, 2012·4 cites·53 claims
- 3067US8722875B2Means for inhibiting the expression of Orc-1GOSSEN MANFRED·Filed 2009·Granted May 13, 2014·1 cites·21 claims
- 3164US2017036990A1Lipids, lipid complexes and use thereofSILENCE THERAPEUTICS GMBH·Filed 2016·Application pending·0 cites
- 3261US11587339B2Method for reading a code stored in a halftone image and comparison with a retrievable valueIND 365 UG HAFTUNGSBESCHRAENKT·Filed 2019·Granted Feb 21, 2023·1 cites·6 claims
- 3361US2024408014A1Preparation for use in a method for the treatment and/or prevention of a diseasePANTHERNA THERAPEUTICS GMBH·Filed 2024·Application pending·0 cites
- 3458US8829179B2Means for inhibiting the expression of ANG2SANTEL ANSGAR·Filed 2010·Granted Sep 9, 2014·1 cites·24 claims
- 3556US2011294871A1Lipids, lipid complexes and use thereofKEIL OLIVER·Filed 2011·Application pending·0 cites
- 3655US9387262B2Coated lipid complexes and their useSILENCE THERAPEUTICS GMBH·Filed 2014·Granted Jul 12, 2016·0 cites·15 claims
- 3754US2023263819A1Lipid Composition and Use Thereof for Delivery of a Therapeutically Active Agent to EndotheliumPANTHERNA THERAPEUTICS GMBH·Filed 2022·Application pending·0 cites
- 3853US9078855B2Further use of protein kinase N betaKLIPPEL-GIESE ANKE·Filed 2012·Granted Jul 14, 2015·0 cites·8 claims
- 3952US2014249207A1Means for inhibiting the expression of orc-1SILENCE THERAPEUTICS GMBH·Filed 2014·Application pending·0 cites
- 4052US2009074852A1Lipoplex formulations for specific delivery to vascular endotheliumSILENCE THERAPEUTICS AG·Filed 2007·Application pending·0 cites
- 4152US2015337382A1Further use of protein kinase n betaSILENCE THERAPEUTICS GMBH·Filed 2015·Application pending·0 cites
- 4250US2016303047A1Means for lung specific deliverySILENCE THERAPEUTICS GMBH·Filed 2014·Application pending·0 cites
- 4350US2011008320A1Further Use of Protein Kinase N BetaSILENCE THERAPEUTICS AG·Filed 2010·Application pending·0 cites
- 4449US9458461B2Means for inhibiting the expression of ANG2SILENCE THERAPEUTICS GMBH·Filed 2014·Granted Oct 4, 2016·0 cites·15 claims
- 4549US2003135033A1Compounds and methods for the identification and/ or validation of a targetFiled 2003·Application pending·0 cites
- 4646US2019038557A1Means for lung specific deliverySILENCE THERAPEUTICS GMBH·Filed 2018·Application pending·0 cites
- 4746US2017296469A1Lipoplex formulations for specific delivery to vascular endotheliumSILENCE THERAPEUTICS GMBH·Filed 2017·Application pending·0 cites
- 4845US11715309B2Method for producing security elements in an image which are not visible to the human eye and cannot be copied, and printed imageIND UG HAFTUNGSBESCHRAENKT·Filed 2019·Granted Aug 1, 2023·0 cites·14 claims
- 4944US2009252783A1Means for inhibiting the expression of cd31SILENCE THERAPEUTICS AG·Filed 2007·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jörg Kaufmann files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →